期刊文献+

重组改构TNF-α与顺铂、吉西他滨联合对H1299细胞系杀伤作用 被引量:4

The killing effect of recombinant mutant human tumor necrosis factor combined with cisplatin or gemcitabine on H1299 cell line
原文传递
导出
摘要 目的观察重组改构肿瘤坏死因子(TNF-α)在体外和顺铂、吉西他滨联合对人肺腺癌H1299细胞系杀伤作用。方法MTT法检测不同浓度TNF-α、顺铂、吉西他滨单药对H1299细胞的抑制率,一定浓度的TNF-α与不同浓度顺铂或吉西他滨联合时对H1299细胞的抑制率,有或无TNF-α作用下H1299细胞的平板克隆形成率和细胞生长曲线,流式细胞仪检测各组细胞凋亡率。结果在不同浓度TNF-α作用下,H1299细胞抑制率均为负值,与药物浓度无明显相关性;TNF-α对H1299细胞的细胞生长曲线和克隆形成率均无明显影响;TNF-α与顺铂联合时在顺铂浓度为10μg/m l时H1299细胞抑制率,明显高于单纯顺铂的作用(P<0.05);TNF-α与吉西他滨联合时在吉西他滨浓度为20、40μg/m l时对H1299细胞抑制率明显高于单纯吉西他滨的作用(P<0.05)。流式细胞分析各组细胞凋亡率与MTT结果一致。结论在体外重组改构肿瘤坏死因子与顺铂或吉西他滨联合应用明显增强后者对H1299细胞的杀伤作用,具有化疗增敏的作用。 Objective To study the killing effect of combining recombinant mutant human tumor necrosis factor (TNF-α) with cisplatin or gemcitabine on H1299 cell line in vitro. Methods MTT method was applied to detect the inhibition ratio of H1299 cells treated by different concentrations of TNF-α, cisplatin or gemcitabine alone, anti 8000 U/ml TNF-α combined with different concentrations of cisplatin or gemcitabine. Cell growth curve and cloning efficiency of H1299 cells treated by TNF-α or nothing were observed. The apoptotic rate of deferent groups were detected by tlow cytometer. Results The inhibition ratio were all minus after H1299 cells treated by different concentration of TNF-α. The cell growth curves and cloning efficiency of H1299 cells treated by TNF-α or nothing showed no evident difference. The inhibition ratio of TNF-α combined with 10μg/ml cisplatin or 20 μg/ml, 40μg/ml gemcitabine were remarkably higher than that of the later in the same concentration alone(P〈0.05). The flow cytometry data of cell apoptosis showed the same result as MTT method's. Conclusion Our data suggest that TNF-α has no proliferative or inhibitive effect on H1299 cell line. But when combined with TNF-α, the killing effect of cisplatin or gemcitabine on H1299 cells was markedly enhanced.
出处 《临床医学》 CAS 2005年第12期1-4,共4页 Clinical Medicine
关键词 重组改构肿瘤坏死因子 化疗增敏 顺铂 吉西他滨 Recombinant mutant human tumor necrosis factor Chemosensitization Cisplatin Gemcitabine
  • 相关文献

参考文献13

  • 1Nakamoto T,Inagawa H,Takagi K,et al.A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.Anticancer Res,2000,20 (6A):4087-4096.
  • 2Darnay BG,Aggarwal BB.Early events in TNF signaling:a story of associations and dissociations.J Leuk Bio,1997,61:559 -566.
  • 3Chan H,Aggarwal BB.Role of tumor necrosis factor receptors in the activation of nuclear factor-κB in human histiocytic lymphoma U-973cells.J Biol Chem,1994,269(50):31424 -31429.
  • 4Park A,Baichwal VR.Systematic mutational analysis of the death domain of the tumor necrosis factor receptor 1-associated protein TRADD.J Biol Chm,1996,271:9858 -9862.
  • 5Muzio M,Chinnaiyan AM,Kischwal FC,et al.FLICE,a novel FADD-homologous ICE/CED-3-like protease,is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex.Cell,1996,85:817 -827.
  • 6Van Antwerp DL,Martin SJ,Kafri T,et al.Suppression of TNF-α -induced apoptosis by NF-κB.Science,1996,274:787 -789.
  • 7Hsu H,Huang J,Shu HB,et al.TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex.Immunity,1996,4:387-396.
  • 8Stanger BZ,Leder P,Lee TH,et al.SB.RIP:a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.Cell,1995,81:513 -523.
  • 9Schutze S,Machleidt T,Kronke M.The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction.J Leuk Bio,1994,56:533 -541.
  • 10陆琰君,曹纬.肿瘤坏死因子在肿瘤研究和治疗领域中的新进展[J].中国肿瘤生物治疗杂志,2002,9(4):297-299. 被引量:42

二级参考文献22

  • 1Eggermont AMM, Schreffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial[J]. Clin Oncol, 1996, 14:2653-2665.
  • 2Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma[J]. Clin Oncol, 1992, 10: 52-60.
  • 3Eggermont AMM. TNF registered in Europe: Does TNF get a second chance? [ J]. J Immunotherapy, 2000, 23: 505-506.
  • 4Chen G, Goeddel DV. TNF-R1 signaling: A beautiful pathway [J]. Science, 2002, 296: 1634-1635.
  • 5Wang CY, Mayo MW, Korneluk RG, et al. NF-κB antiapoptosis:Induction of TRAF1 and TRAF2 and c-IAp1 and c-IAp2 to suppress caspase-8 activation[J]. Science, 1998, 281: 1680-1683.
  • 6Guttridge DC, Mayo MW, Madrid LV, et al. NF-κB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia[ J]. Science, 2000, 289: 2363-2365.
  • 7Kyriaks JM. Life-or-death decisions[J]. Nature, 2001, 414:265 -266.
  • 8Schulg A, Bauer G. Selective effect of tumor necrosis factor on transformed Versus Nontransformed cells: Nonselective signal recognition but differential target cell response[J]. Anticancer Res, 2000, 20: 3435-3442.
  • 9Shimpmura K, Manda T, Mukumoto S, et al. Recombinant human tumor necrosis factor-α: Thrombus formation is a cause of antitumor activity[J]. Int J Cancer, 1988, 41: 243-247.
  • 10Ruegg C, Yimaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin αvβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ[ J]. Nat Med, 1998,4: 408-414.

共引文献48

同被引文献39

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部